Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone vs Haloperidol for Relapse Prevention in Schizophrenia
NCT00253110Phase 4Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 1996
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial of risperidone in schizophrenia and schizoaffective disorder (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Time to relapse up to 112 weeks. Started May 1996; status: completed.
02
Drugs
risperidone
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT00253110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00253110.